LEXINGTON, MA - Synta Pharmaceuticals Corp. is planning to float its shares in the public markets, according to a recent filing with the SEC.
The filing suggests the company will seek up to $115 million, nearly 18 months after pulling a previous IPO due to uncertain market conditions.
The company has one cancer drug that is near late-stage trials and several others that are in mid-stage trials for Crohn's disease and cancer.